Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir

作者：Lijun Ling, Manse Kim, Andrew Soper, Martina Kovářová, Rae Ann Spagnuolo, Nurjahan Begum, Jennifer Kirchherr, Nancie M. Archin, Diana M. Battaglia, Dave Cleveland, Angela Wahl, David M. Margolis, Edward P. Browne, J. Víctor García · 发表于：mBio · 年份：2024 · DOI：10.1128/mbio.01632-24 · 被引用次数：14 · 研究领域：HIV Research and Treatment、HIV/AIDS Research and Interventions、HIV/AIDS drug development and treatment

ABSTRACT The HIV reservoir is more dynamic than previously thought with around 70% of the latent reservoir originating from viruses circulating within 1 year of the initiation of antiretroviral therapy (ART). In an ex vivo model system of HIV latency, it was reported that early exposure to class I histone deacetylase (HDAC) inhibitors might prevent these more recently infected cells from entering a state of stable viral latency. This finding raises the possibility that co-administration of HDAC inhibitors at the time of ART initiation may prevent the establishment of much of the HIV reservoir. Here, we tested the effects of the HDAC inhibitors suberoylanilide hydroxamic acid (SAHA) and panobinostat co-administered at the time of ART initiation on the formation of the viral reservoir in HIV-infected humanized mice. As previously shown, SAHA and panobinostat were well tolerated in humanized mice. Unexpectedly, co-administration of SAHA resulted in an increase in the frequency of CD4 + cells carrying HIV DNA but did not alter the frequency of cell-associated HIV RNA in HIV-infected, ART-treated humanized mice. Co-administration of panobinostat did not alter levels of cell-associated HIV DNA or RNA. Our in vivo findings indicate that co-administration of HDAC inhibitors initiated at the same time of ART treatment does not prevent recently infected cells from entering latency. IMPORTANCE Current antiretroviral therapy (ART) does not eradicate cells harboring replication-competent ...